Related references
Note: Only part of the references are listed.How do biosimilars sustain value, affordability, and access to oncology care?
Steven Simoens
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis
Conor Hanrahan et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
Dmytro Trukhin et al.
BIODRUGS (2021)
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
Konstantinos Syrigos et al.
BIODRUGS (2021)
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study
Shukui Qin et al.
BIODRUGS (2021)
Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies
Aqsa Safdar et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial
Yuankai Shi et al.
CANCER COMMUNICATIONS (2021)
Safety and efficacy of bevacizumab biosimilar in recurrent/progressive glioblastoma
Gunjesh Kumar et al.
ECANCERMEDICALSCIENCE (2021)
Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial
Hamid Rezvani et al.
CLINICAL THERAPEUTICS (2020)
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer
Martin Reck et al.
LUNG CANCER (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Cancer statistics for adolescents and young adults, 2020
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials
Sarah Cargnin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Bayesian Random-Effects Meta-Analysis Using the bayesmeta R Package
Christian Roever
JOURNAL OF STATISTICAL SOFTWARE (2020)
GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence
Romina Brignardello-Petersen et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jichun Yang et al.
BIODRUGS (2019)
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Niels Reinmuth et al.
BIODRUGS (2019)
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer
Yunpeng Yang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients
Edoardo Botteri et al.
EUROPEAN JOURNAL OF CANCER (2018)
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
Romina Brignardello-Petersen et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2018)
Biosimilars: Review of current applications, obstacles, and their future in medicine
Flyn Kaida-Yip et al.
WORLD JOURNAL OF CLINICAL CASES (2018)
Current Status of Biosimilars in Oncology
Luis H. Camacho
DRUGS (2017)
A Bayesian network meta-analysis for binary outcome: how to do it
Teresa Greco et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer
Lindsey E. Minion et al.
GYNECOLOGIC ONCOLOGY (2015)
Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases
Alexander Nast et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2015)
Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries
Ivo Abraham et al.
FUTURE ONCOLOGY (2014)
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
Milo A. Puhan et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Conceptual and Technical Challenges in Network Meta-analysis
Andrea Cipriani et al.
ANNALS OF INTERNAL MEDICINE (2013)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
A basic introduction to fixed-effect and random-effects models for meta-analysis
Michael Borenstein et al.
RESEARCH SYNTHESIS METHODS (2010)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Share Paper
